KOL Perspectives: Implementation of the treat-to-target approach in IBD
Orbisresearch.com published “Implementation of the treat-to-target approach in IBD Market” from its database. The report focuses on major leading industry players with information such as company profiles, product picture and specification.
(EMAILWIRE.COM, October 24, 2018 ) This KOL Insight briefing focuses on KOLs views of implementation of the treat-to-target approach in IBD.
The briefing includes analysis of KOL opinion on the following topic areas -
- Perceptions of the CALM study and potential impact on Crohn’s disease clinical management
- Adoption of a T2T approach in UC
- Impact of T2T studies on choice of therapy
- Monitoring mucosal healing in IBD
Key Players:
• AbbVie
• Prometheus
• Janssen
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2350562
Key Highlights:
- Most KOLs view the data from the CALM study as supportive of the concept of a T2T strategy in Crohn’s disease
- T2T is used routinely in clinical practice, with an increase in a patient’s disease severity used as a driver for adoption of the strategy
- Over half the KOLs expect the CALM study to positively influence Crohn’s disease management across clinical practice.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based
- Interviews performed during December 2017
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350562
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "implementation of a treat-to-target (T2T) approach in IBD"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
The briefing includes analysis of KOL opinion on the following topic areas -
- Perceptions of the CALM study and potential impact on Crohn’s disease clinical management
- Adoption of a T2T approach in UC
- Impact of T2T studies on choice of therapy
- Monitoring mucosal healing in IBD
Key Players:
• AbbVie
• Prometheus
• Janssen
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2350562
Key Highlights:
- Most KOLs view the data from the CALM study as supportive of the concept of a T2T strategy in Crohn’s disease
- T2T is used routinely in clinical practice, with an increase in a patient’s disease severity used as a driver for adoption of the strategy
- Over half the KOLs expect the CALM study to positively influence Crohn’s disease management across clinical practice.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based
- Interviews performed during December 2017
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350562
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "implementation of a treat-to-target (T2T) approach in IBD"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results